(BWAY) BrainsWay Ltd. SWOT Analysis Research

Founded in 2003, BrainsWay has more than 23 years of operating history by July 2026. That long record can strengthen brand recognition and make clinicians more familiar with its transcranial magnetic stimulation platform.

A 2003 start also signals staying power in a regulated medtech market, where trust and repeated clinical use matter. Longer history can help support customer confidence, payer discussions, and broader market acceptance.

• Founded in 2003
• 23+ years by July 2026
• Supports clinical familiarity
• Can aid brand trust

BrainsWay’s customer base is anchored in healthcare providers—psychiatrists, hospitals, and medical centers—so each sale is tied directly to treatment delivery, not consumer demand. That makes adoption easier in in-clinic care settings, where therapy decisions, patient flow, and reimbursement are already managed inside the provider network. The installed base exceeded 1,000 systems across 50+ countries, showing broad institutional reach.

• Provider-led buying supports faster clinical adoption
• Hospital use fits in-clinic treatment workflows
• Global installed base tops 1,000 systems

BrainsWay’s broad indication set is a weakness because each use case needs its own clinical proof, physician buy-in, and payer coverage. That raises the cost and time to defend value across the portfolio, especially when one weak label can slow adoption for the rest.

• More indications mean more evidence work
• Reimbursement must be won twice
• Physician trust takes repeated validation

BrainsWay Ltd.’s international footprint makes execution harder because each market needs its own regulatory path, sales motion, and service support. That raises fixed costs and slows scale versus a single-country model. The risk is higher operating burden and uneven rollout across regions.

• Multiple regulators
• Separate sales teams
• Higher service load

BrainsWay Ltd. sells mainly to hospitals and medical centers, so larger care-network wins can lift treatment volume fast. With more than 1,700 Deep TMS systems installed worldwide, each new system also raises brand reach among referring clinicians.

That matters because wider institutional use can add capacity without long clinic buildouts. If one health system adds several sites, BrainsWay can expand access across many patients and support repeat referrals.

• Hospitals are the core buyer set.
• Larger networks can scale throughput.
• More sites can boost referrals.

BrainsWay Ltd.’s dTMS is a non-invasive therapy, so it fits the care path many clinicians and patients prefer over surgery or systemic drugs. In major depressive disorder, about 1 in 5 adults had symptoms in 2025 data, and non-drug options matter when side effects or adherence limit meds. That keeps dTMS well placed in neurostimulation settings.

• Non-invasive, no surgery
• Fits drug-avoidance demand
• Supports clinic adoption

Clinical adoption risk is still real for BrainsWay Ltd.: physicians usually want strong, condition-specific outcomes before changing practice, and broad claims can draw skepticism when evidence is uneven. That can slow uptake, and slower adoption means slower installed-base growth and weaker recurring revenue traction.

• Need stronger proof for each indication
• Broad claims can face physician skepticism
• Slower adoption limits installed-base growth

Healthcare spending pressure can delay hospital purchases, and BrainsWay Ltd. may see longer sales cycles for its capital equipment. U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, but budget stress still pushes non-urgent buys out. Weak macro conditions can also slow service expansion and move demand into later quarters.

• Budget cuts defer capital buys.
• Service rollout can slow.
• Demand timing shifts with the economy.